• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Rewired immune cells respond as targeted cancer therapy

December 13, 2016 By Sarah Faulkner

Rewired immune cells respond as targeted cancer therapyResearchers from Northwestern University have developed a method to rewire immune cells by genetically modifying the cells to sense molecules secreted by tumors and respond by activating the immune system. The team’s work is described in a study published this month in Nature Chemical Biology. 

Although immunotherapy is growing in popularity among cancer researchers, tumors secrete molecules that render most immune cells inactive. “Right now, one of the most promising frontiers in cancer treatment is immunotherapy – harnessing the immune system to combat a wide range of cancers,” senior author Joshua Leonard said in prepared remarks. “The simple cell rewiring we’ve done ultimately could help overcome immunosuppression at the tumor site, one of the most intransigent barriers to making progress in this field.”

“This work is exciting because it addresses a key technical gap in the field,” first author Kelly Schwarz said. “There is great promise for using engineered cells as programmable therapies, and it is going to take technologies such as this to truly realize that goal.”

The team genetically engineered human T cells to sense a protein found in tumors called vascular endothelial growth factor. When the rewired cells detect the growth factor, they release a protein, interleukin 2, which stimulates nearby immune cells to actively respond at the site of the tumor. Unmodified T cells do not produce interleukin 2 when exposed to vascular endothelial growth factor.

So far, the team has tested their rewired cells in culture and will soon move to test it in animal studies.

“To truly accelerate the rate at which we can translate scientific insights into treatments, we need technologies that let us rapidly try out new ideas, in this case by building living cells that manifest a desired biological function,” Leonard said. “Our technology also provides a powerful new tool for fundamental research, enabling biologists to test otherwise untestable theories about how cells coordinate their functions in complex, multicellular organisms.”

Filed Under: Featured, Immunotherapy, Oncology, Research & Development Tagged With: Northwestern University

IN CASE YOU MISSED IT

  • Senseonics stock is up as it sticks by revenue guidance
  • MedAlliance wins second FDA IDE nod for drug-coated balloon
  • Wells Fargo downgrades Tandem amid rise of automated insulin delivery competition
  • FDA approves first targeted infusion therapy for HER2-low breast cancer
  • Abbott, WeightWatchers partner on diabetes care

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS